Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6TGC4

UPID:
PADI6_HUMAN

ALTERNATIVE NAMES:
Peptidyl arginine deiminase-like protein; Peptidylarginine deiminase VI; Protein-arginine deiminase type VI

ALTERNATIVE UPACC:
Q6TGC4; Q330K5; Q70SX3

BACKGROUND:
Peptidyl arginine deiminase-like protein, identified as Protein-arginine deiminase type-6, is instrumental in the deimination of arginine residues, a modification essential for early embryonic development. Its activity is linked to cytoskeletal changes necessary for the egg and embryo's structural organization.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in early stages of embryonic development, Protein-arginine deiminase type-6 is a key target in understanding infertility disorders such as Oocyte/zygote/embryo maturation arrest 16. Exploring this protein's mechanisms offers a promising avenue for developing novel infertility treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.